https://www.selleckchem.com/EGFR(HER).html
primary ER or open surgery. Fabry disease (FD) is a lysosomal storage disease, treatable by enzyme replacement therapy (ERT) that substitutes deficient α-galactosidase A (AGAL). The formation of neutralizing anti-drug antibodies (ADA) inhibiting AGAL activity is associated with disease progression in affected male patients. In the current study, we performed a detailed epitope mapping of ADAs from antibody-positive males against infused AGAL. A detailed epitope mapping for 34 male FD patients with neutralizing ADAs against AGAL was performed.
Like
Comment
Share
